. 2019 Jul 16;30(7):794–801. doi: 10.1089/hum.2019.006

Table 2.

Functional outcomes of ILI gene transfer

Subject	MVICT		MF size, μμm (X ±SD)		Ambulatory status pre and post gene therapy	6MWT change BL
Subject	Right	Left	Pre	Post	Ambulatory status pre and post gene therapy	6MWT change BL
E-01	Pre 2.77	Pre 3.33	—	Post TA^a Quad not available	Non-AMB pre gene therapy; non-AMB post gene therapy	^*
	Post 4.07	Post 3.91
	Δ↑47%	Δ ↑17%
E-02	Pre 1.87	Pre 3.44	—	No post Bx	AMB pre gene therapy; lost AMB post gene therapy	^**
	Post 1.46	Post 2.48
	Δ ↓22%	Δ↓28%
E-03	Pre 36.83	Pre 36.22	Pre 56.19 (17.43)	Post 72.30 (26.05)	AMB pre gene therapy; AMB post gene therapy	Pre 538 m
	Post 58.41	Post 60.92				Post 525 m
	Δ ↑59%	Δ ↑68%				Δ ↓2%
E-04	Pre 11.45	Pre 8.43	Pre 49.85 (16.64)	Post 35.12 (27.58)	AMB pre gene therapy; AMB post gene therapy	Pre 487 m
	Post 7.43	Post 4.33				Post 366 m
	Δ ↓35%	Δ ↓49%				Δ ↓24%
E-05	Pre 5.14	Pre 4.96	Pre 62.13 (24.97)	Post 67.38 (22.84)	AMB pre gene therapy; lost AMB post gene therapy	^**
	Post 5.07	Post 4.74
	Δ ↓1%	Δ↓4%
E-06	Pre 10.61	Pre 11.01	Pre 46.39 (14.56)	Post 32.09 (10.63)	AMB pre gene therapy; AMB post gene therapy	Pre 571 m
	Post 8.14	Post 9.45			AMB pre gene therapy; AMB post gene therapy	Post 600 m
	Δ ↓23%	Δ ↓14%				Δ ↑5%

^{^a}

Post gene-transfer muscle biopsy done on TA.

^{^*}

No ambulatory change pre and post gene therapy.

^{^**}

Lost ambulation post gene therapy.

ILI, isolated limb infusion; MVICT, maximum voluntary isometric contraction testing (reported in kilograms); 6MWT, six-minute walk test (reported as distance walked in meters); BL, baseline; AMB, ambulation; TA, tibialis anterior; Δ, percent change in 6MWT meters from baseline to end of study (all patients completed 2 years).